Select a medication above to begin.
Imdelltra (tarlatamab-dlle)
tarlatamab
Black Box Warnings .
Cytokine Release Syndrome
incl. serious or life-threatening rxn, occurred in 55% of pts; initiate tx using step-up dosing schedule in cycle 1, admin. concomitant meds before and after cycle 1 infusions to reduce CRS incidence and severity; admin. at appropriate healthcare facility, monitor pts x22-24h post-infusion at facility on days 1 and 8 of cycle 1, recommend pts remain w/in 1h of facility w/ caregiver x48h after days 1 and 8 of cycle 1 infusions, then monitor s/sx during tx and counsel pts to seek immediate medical attention if s/sx of CRS occur; withhold tx until CRS resolves or permanently D/C tx based on severity
Neurological Toxicities
incl. immune effector cell-associated neurotoxicity syndrome (ICANS), incl. serious or life-threatening rxn, occurred in 47% of pts; monitor pts for s/sx during tx and treat promptly; withhold tx until ICANS resolves or permanently D/C tx based on severity
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = tarlatamab-dlle
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, concomitant meds, and dosing incl. toxicity-related dose adjustments
small cell lung CA, extensive-stage
- [10 mg IV x1 on days 1, 15 of 28-day cycle, starting cycle 2]
- Start: 1 mg IV x1 on day 1, then 10 mg IV x1 on day 8, then 10 mg IV x1 on day 15 of 28-day cycle for cycle 1; Info: for pts w/ dz progression on or after platinum-based chemo
renal dosing
- [see below]
- eGFR >30: no adjustment; eGFR <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- mild impairment: no adjustment; moderate-severe impairment: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.